Prostate Cancer
Advertisement
Standard risk assessment plus genomic classification for prostate cancer surveillance helps predict disease progression.
The panel explores the distinct roles of alpha and beta emitters in radiopharmaceutical therapy for prostate cancer care.
The expert panel discusses emerging biomarkers and treatment combinations for CRPC and mHSPC.
The evolving role of RLT and radium-223 in managing metastatic mHSPC and CRPC is discussed.
The panel examines the impact of the latest data from ARANOTE and PEACE-3 in part three of this roundtable.
The panelists discuss key considerations for patient selection in doublet and triplet therapies for mHSPC and CRPC.
In part one of this roundtable, the panel discusses advances in imaging and tailored treatment strategies for prostate cancer
Drs. Saji and Lebastchi provide an in-depth overview of focal therapy for prostate cancer, including HIFU and IRE therapies.
Radical prostatectomy with pelvic lymph node dissection increases risks of complications like DVT and lymphatic leaks.
The phase 3 trial evaluates combination mevrometostat in patients with mCRPC previously treated with abiraterone acetate.
The real-world analysis of olaparib for HRRm+ CRPC showed that earlier treatment resulted in higher PFS and OS.
Dr. Brown shares highlights from the CME program at LUPGA 2024, including new trends in bladder, kidney, and prostate cancer.
Ana Kiess, MD, PhD, of Johns Hopkins Medicine, reviews the phase II RAVENS trial on radium-223 with SABR versus SABR alone.
Dr. Sartor offers insight on the efficacy of 177Lu-PSMA-617 in prolonging progression-free survival rates.
A recent study assessed pathologic and short-term oncological and survival outcomes of prostate cancer surgical approaches.
The phase II UpFrontPSMA study evaluated the use of [177Lu]Lu-PSMA-617 administered before docetaxel.
Clarity's head-to-head trial evaluates diagnostic performance of 64Cu-SAR-bisPSMA vs 68Ga-PSMA-11.
In part six of this roundtable series, the panelists finish their discussion by reviewing immunotherapy in prostate cancer.
In part five of this roundtable series, the panelists discuss radiopharmaceuticals in the overall landscape of mCRPC.
In part four of this roundtable series, the panelists discuss CRPC and the typical patterns of presentation.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.